First Closings of Seed Round

Munich, March 3, 2025 – Cardiogen GmbH, a preclinical clinical life science company focusing on cardiovascular regeneration and cellular reprogramming, announced first closings of its Seed financing round.

Closing of Seed Round

This financing and closings include new undisclosed investors. The current proceeds will be used to complete the preclinical development for Cardiogen’s lead therapeutic candidate, CGN 001, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack. The financing will also support the preparation for the start of the clinical development of Cardiogen.

“This year will be exciting for Cardiogen as we are completing our preclinical development for the IND submission in AMI, one of the most promising indications from our cardiovascular platform technology” said Dr. Roman Schenk, Cardiogen’s Board Member and co-founder.

About Cardiogen

Cardiogen’s non-invasive regenerative approach can potentially play a significant role in improving the survival rate and quality of life for patients who experience a heart attack, as well as in various other cardiovascular diseases. 

For more information, visit: https://www.cardiogentx.com/ or contact info@cardiogentx.com